Stock Analysis of ABVC Biopharma Inc (ABVC) - Birds Eye View

1W   2W   1M   3M   1Y   2Y   5Y   
Overview
Code ABVC
Close 1.07
Change 0.0100 / 0.943 %
Volume 188389
Vol Change -18254.00 / 8.83 %
IndustryBiotechnology
SectorHealthcare
AIO Strength Index
Technical StrengthBearish
Growth Index No Significant Growth
Value Index Very Low Value Stock
Profitability Index Poor Profitability Stock
Stability Index Very Low Stability Stock


Fundamental View of ABVC Biopharma Inc
PE (TTM)

-0.470

Very Poor
Price / Book

0.951

Very Good
Price / Sales

27.21

Very Poor
Piotroski F Score

2.0

Poor
Market Cap

11299.63 K

Enterprise Value

13283.14 K

ROA (TTM)

-72.28

Very Poor
ROE (TTM)

-201.51

Very Poor
Net Margin (TTM)

-5784.43

Very Poor
Revenue

23.77 %

739259
Net Profit

24.79 %

-12268.66 K
Debt to Equity

0.244

Excellent
Altman Z Score

-8.00

Very Poor
Quick Ratio

0

Poor
Cash Ratio

0.134

Poor


Highs/Lows of ABVC Biopharma Inc
PeriodOld priceStock ReturnS&P 500 ReturnsHighLowHigh DateLow Date
One Week1.08 0.926 % 0.785 % 1.241.0309-May-2407-May-24
Two Week1.4 23.57 % 2.06 % 1.411.0330-Apr-2407-May-24
One Month1.09 1.83 % 1.91 % 1.730.9425-Apr-2418-Apr-24
Three Month1.32 18.94 % 5.42 % 1.730.9425-Apr-2418-Apr-24
Six Months1.14 6.14 % 18.36 % 2.220.9421-Nov-2318-Apr-24
One year8.266 87.06 % 26.61 % 8.10.69718-May-2306-Oct-23
Two year22.5 95.24 % 29.76 % 18.70.69705-Jan-2306-Oct-23
Five year12.5 91.44 % 85.69 % 18.70.33305-Jan-2324-Jul-23
Ten year0.0031837 33508.69 % 175.18 % 29.953.1837E-410-May-2122-Jan-15


Technical View of ABVC Biopharma Inc
RSI

43.37

Neutral
MACD

-0.0363

Bearish
ADX

18.93

Neutral
Super Trend

1.06

Mild Bullish
Williams %R

-94.29

Mild Bearish
CCI

-41.27

Neutral


EMA 5

1.09

Strong Bearish
EMA 15

1.14

Mild Bearish
EMA 50

1.20

Strong Bearish
EMA 100

1.31

Mild Bearish
SMA 100

1.25

Mild Bearish
SMA 200

1.32

Mild Bearish
SMA 5 / 20

1.08 / 1.18

Strong Bearish
SMA 15 / 50

1.22 / 1.19

Mild Bullish
SMA 50 / 200

1.19 / 1.32

Mild Bearish




Charts of ABVC Biopharma Inc


Returns of ABVC Biopharma Inc with Peers
Period / StockABVCERNACMMBAVTX
1 Week-0.926%21.59%-4.55%-19.91%
1 Mth-1.83%-4.46%5.74%-27.38%
3 Mth-18.94%28.14%34.55%124.95%
6mth-6.14%86.09%48.00%-50.46%
1 Year-87.06%-22.74%-48.48%-98.17%
2 Year-95.24%-86.59%-70.82%-98.50%
5 Years-91.44%-98.47%-99.94%-99.92%
charts-
View All Together in Chart      Inline           Tile

Compare Fundamentals of ABVC Biopharma Inc with Peers
Ratio / StockABVCERNACMMBAVTX
PE-0.470-0.525-2.73-0.095
P/B0.9511.952.69-6.98
ROA-72.28-58.33-76.13-109.45
ROE-201.51-371.64-98.680
Debt To Equity0.2444.030.00450.074
Revenue739259
23.77 % 		51000.00
% 		0
% 		2249.00 K
87.54 %
Net Income-12268.66 K
24.79 % 		-20004.00 K
18.61 % 		-24158.59 K
12.61 % 		-33188.00 K
20.33 %


Technicals of ABVC Biopharma Inc with Peers
Technical / StockABVCERNACMMBAVTX-
ADX18.9323.5720.7127.56
CMF0.342-0.00660.0123-0.350
MFI68.8167.5083.4551.08
RSI43.3755.4855.8740.38
MACD Abv SignalFalseTrueTrueFalse
Price Above 50 MAFalseTrueTrueFalse-
Price Above 200 MAFalseTrueTrueFalse-


About : ABVC Biopharma Inc

Address : 44370 Old Warm Springs Boulevard, Fremont, CA, United States, 94538
Tel : (510)-668-0881
URL : https://www.abvcpharma.com
Code : ABVC, ISIN : US00091F1066, Exchange : NASDAQ, Country : USA
Fiscal Year End : December
IPO date : 11_Oct_2017
Employee Count : 16

ABVC BioPharma, Inc., a clinical stage biopharmaceutical company, develops drugs and medical devices to fulfill unmet medical needs in the United States. The company is developing ABV-1501, which is in Phase II clinical trials a combination therapy for triple negative breast cancer; ABV-1504 has completed Phase II clinical trials for major depressive disorders; ABV-1505, which is in Phase II clinical trials for adult attention deficit hyperactivity disorder; ABV-1703, which is in Phase II clinical trials for the treatment of metastatic pancreatic cancer; ABV-1702, which is in Phase II clinical trials to treat myelodysplastic syndromes; and ABV-1601 that is in Phase I/II clinical trials for treating depression in cancer patients. It is also developing ABV-1701 Vitargus that is in Phase II clinical trials for the treatment of retinal detachment or vitreous hemorrhage; and ABV-1519, which is in Phase I/II clinical trials for the treatment of non-small cell lung cancer. ABVC BioPharma, Inc. has a co-development agreement with Rgene Corporation; and collaboration agreements with BioHopeKing Corporation and BioFirst Corporation. The company is based in Fremont, California. ABVC BioPharma, Inc. operates as a subsidiary of YuanGene Corporation.


Note : All Data Generated at the End of Trading Hours (EOD Data)